PCVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vaxcyte Inc (PCVX) does not currently present a strong buy opportunity for a beginner investor with a long-term strategy. While the company has promising catalysts like the VAX-31 Phase 3 data and strong analyst support, the technical indicators and financial performance suggest caution. The stock is trading near a key support level, and there are no immediate signals or news to suggest a significant upward movement in the short term.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 25.473, and moving averages are converging, showing no clear trend. The stock is trading near its S1 support level of 53.96, with resistance at 56.714. Overall, the technical indicators suggest a lack of strong upward momentum.
Strong analyst support with multiple Buy ratings and increased price targets, driven by the promising potential of VAX-31 and its Phase 3 data. Analysts view the vaccine as having best-in-class potential for both adults and children.
No significant news or events in the past week. Financial performance remains weak, with negative net income and EPS despite YoY improvement. Hedge funds and insiders show neutral trading trends, indicating no strong institutional or insider confidence.
In Q4 2025, the company reported a net income of -$246.5 million, improving 79.83% YoY. EPS increased to -1.81, up 79.21% YoY. However, revenue and gross margin remain at 0, indicating no revenue generation yet.
Analysts are bullish overall, with multiple Buy ratings and price targets ranging from $67 to $133. Key catalysts include the upcoming Phase 3 adult data and Phase 2 pediatric readouts for VAX-31. However, one analyst maintains a Neutral rating, citing slower-than-expected competitive developments.
